Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Inc HOOK amended and restated collaboration and license agreement with Gilead Sciences Inc GILD for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).

  • In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). 
  • The companies agreed to collaborate through a joint research phase, after which Gilead had rights for further development. 
  • Under the amended and restated agreement, Hookipa will advance the HIV program through the Phase 1b trial, with funding from Gilead via an upfront payment and equity purchases. 
  • After the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged.
  • Hookipa earned a one-time $4 million preclinical milestone payment under the original 2018 agreement. 
  • Upon signing of the amended agreement, Hookipa will receive $15 million. 
  • In addition, Gilead will make a $5 million equity investment in Hookipa and up to an additional $30 million of equity financing that can be drawn at HOOKIPA's discretion by December 31, 2023.
  • Gilead plans to advance the Hepatitis B virus (HBV) program to the IND-enabling stage in 2022.
  • Price Action: HOOK shares are up 41.8% at $1.90 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!